Calcimimetic Compounds: a Direct Approach to Controlling Plasma Levels of Parathyroid Hormone in Hyperparathyroidism

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• The calcium (Ca2+) receptor regulates parathyroid hormone (PTH) secretion.
• Hyperparathyroidism (HPT) involves elevated PTH levels, posing a significant health challenge.
• Calcimimetics are ligands that activate the Ca2+ receptor, offering a novel therapeutic approach.

Purpose of the Study:

• To investigate the efficacy of two distinct classes of calcimimetics in inhibiting PTH secretion.
• To evaluate the therapeutic potential of phenylalkylamine calcimimetics for primary and secondary HPT.

Main Methods:

• Identification and characterization of type I (full agonists) and type II (positive allosteric activators) calcimimetics.
• Assessment of oral activity and effects on plasma PTH and Ca2+ levels in preclinical models (rats) and human patients.
• Evaluation of calcimimetics' impact on parathyroid cell hyperplasia in HPT models.

Main Results:

• Type II phenylalkylamine calcimimetics are orally active, stereoselective positive allosteric activators of the Ca2+ receptor.
• These compounds significantly decrease plasma PTH and Ca2+ levels in patients with primary HPT.
• Calcimimetics demonstrate safety and efficacy in reducing PTH and preventing hyperplasia in rat models of secondary HPT and in human dialysis patients.

Conclusions:

• Calcimimetic compounds, particularly phenylalkylamines, represent a novel and effective pharmacological intervention for hyperparathyroidism.
• These agents offer a promising therapeutic strategy for both primary HPT and secondary HPT associated with chronic renal disease.
• Calcimimetics may provide a much-needed treatment option for a condition previously resistant to pharmacological management.